5/21/2021 8:10:44 AM
Regulus Therapeutics Report Incremental Update From First Cohort Of Patients With ADPKD In RGLS4326 Phase 1b Trial
5/3/2021 8:16:15 AM
Regulus Therapeutics Announces Top-Line Data From First Cohort Of Phase 1b Clinical Trial Of RGLS4326
4/15/2021 8:31:05 AM
Regulus Therapeutics Completes Dosing In First Cohort Of Phase 1b Trial Of RGLS4326 For ADPKD
3/9/2021 4:08:34 PM
Regulus Therapeutics Q4 Loss/share $0.03 Vs. Loss $0.23 Year Ago
2/10/2021 8:11:24 AM
Regulus Completes Enrollment In First Cohort Of Phase 1b Trial Of RGLS4326 For Treatment Of Patients With ADPKD
1/27/2021 8:08:19 AM
Regulus Therapeutics Names Alice Huang To Board Of Directors
12/2/2020 7:11:07 AM
Regulus Therapeutics, Bio-Techne Collaborate For Biomarker Development
11/2/2020 8:11:19 AM
Regulus Announces Achievement Of Interim Enrollment Milestone In Sanofi Collaboration; To Get Remaining $5 Mln Payment
8/31/2020 8:16:45 AM
Regulus Therapeutics Reports Restructuring Of Sanofi And Oxford Loan Agreements
7/29/2020 8:13:30 AM
Regulus Therapeutics Announces FDA Orphan Drug Designation Of RGLS4326 For ADPKD Treatment
7/22/2020 8:14:39 AM
Regulus Therapeutics Completes Dosing In Phase 1 Multiple Ascending Dose Study Of RGLS4326